3-Anilino-4-arylmaleimides: potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3).
Potent 3-anilino-4-arylmaleimide glycogen synthase kinase-3 (GSK-3) inhibitors have been prepared using automated array methodology. A number of these are highly selective, having little inhibitory potency against more than 20 other protein kinases.
SmithKline Beecham Pharmaceuticals, New Frontiers Science Park, Harlow, Essex, UK. dave_g_smith@sbphrd.com
D G
DG
Smith
M
M
Buffet
A E
AE
Fenwick
D
D
Haigh
R J
RJ
Ife
M
M
Saunders
B P
BP
Slingsby
R
R
Stacey
R W
RW
Ward
D000818:Animals; D001714:Bipolar Disorder / Q000188:drug therapy; D017871:Calcium-Calmodulin-Dependent Protein Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D038341:Glycogen Synthase Kinases; D006801:Humans; D008301:Maleimides / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D015394:Molecular Structure; D013329:Structure-Activity Relationship
D004791:Enzyme Inhibitors; D008301:Maleimides; D038341:Glycogen Synthase Kinases; D017871:Calcium-Calmodulin-Dependent Protein Kinases